Research presented at ENDO 2026, the Endocrine Society’s annual meeting in Chicago, found that taking a GLP-1 medication for weight loss may improve male fertility. The study explored how obesity is strongly linked to fertility problems in men.
How GLP-1 Medications Impact Reproductive Hormones
The researchers evaluated how GLP-1 weight-loss drugs impact reproductive hormones and metabolic outcomes, analyzing data of men between the ages of 18 and 65 who were taking one of the medications. The results suggested that GLP-1 medications do not suppress male hormones. Men with obesity and low testosterone linked to obesity may experience improved testosterone, sperm quality, and metabolic health, especially during weight loss.
In one four-week study, dulaglutide showed no significant changes in reproductive hormones or sexual function. In a separate 16-week trial, liraglutide improved hormones in obese men with functional hypogonadism, meaning low testosterone was likely related to obesity. The review found that liraglutide was better for health outcomes than hormone replacement therapy.
A 24-week trial of semaglutide, known commercially as Ozempic and Wegovy, saw improvement in sperm shape and bad cholesterol, while preserving total testosterone. While more research is necessary, the findings provide early evidence that GLP-1 medications taken by obese men with hypogonadism/low testosterone (low T) improves testosterone levels.
Original reporting: Fox News (HLL/CB) — read the source article.
